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Abstract 
Objective: Since the Mediterranean diet (MD) is a dietary pattern with several health benefits, but 
adherence and its effects in patients with Crohn’s Disease (CD) have not yet been investigated, the 
objectives of the present study were a) to assess the adherence to MD in patients with CD and b) to 
examine the association of adherence to MD with quality of life, disease activity and inflammatory 
markers. 
Design: Outpatients with CD were enrolled in this protocol. Medical history, disease activity, dietary 
intake, habitual Mediterranean Diet (MedDiet) score, anthropometric measurements and Inflammatory 
Bowel Disease Questionnaire (IBDQ) were recorded. Blood samples were collected for quantification 
of biochemical and inflammatory indices. Statistical analysis was conducted with the SPSS software. 
Results: A total of 86 patients with CD were enrolled: 41 in relapse (5≤ Harvey Bradshaw Index ≤14) 
and 45 in remission (Harvey Bradshaw Index ≤4). Adherence to MD was greater in patients with 
inactive disease. The MedDiet score correlated positively with the IBDQ (p=0.008) and negatively with 
disease activity (p<0.001).  
Conclusion: Adherence to MD is associated with improved quality of life in CD patients. Counselling 
regarding the MD could therefore be of importance in patients with CD to improve quality of life and 
reduce disease activity. 
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Summary “box” 
 
What is already known about this subject? 
 Nutrition seems to play a role both in the development and the management of 
IBD. 
 Mediterranean diet (MD) is a dietary pattern with several health benefits. 
 Adherence to MD and its effects in patients with Crohn’s Disease (CD) have not 
yet been investigated. 
 
What are the new findings? 
 Adherence to MD is positively associated with improved quality of life and 
negatively with disease activity. 
 Adherence to MD is greater in patients with inactive CD compared with active 
CD. 
 
How might it impact on clinical practice in the foreseeable future? 
 Counseling regarding the Mediterranean diet should be considered in patients with 
CD as a dietary treatment approach to improve quality of life and reduce disease 
activity. 
 
 
 
Keywords: Mediterranean diet; Crohn’s disease; Quality of life; Systemic Inflammation 
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INTRODUCTION  
Inflammatory Bowel Disease (IBD) - a chronic gastrointestinal condition including 
Crohn’s Disease (CD) and Ulcerative Colitis (UC) - is considered a global challenge 
(Ng et al., 2018). Patients experience periods of relapse and remission, while the 
prolonged nature of IBD affects health-related quality of life, economic productivity and 
social function. 
Nutrition seems to play a role both in the development and the management of IBD. 
Western diets may increase the risk for IBD, while Mediterranean diet (MD) may 
exhibit a protective effect (Gentschew & Ferguson, 2012; Hou et al., 2011).  
Some dietary patterns have been of interest in IBD, such as low-FODMAP diet (Gibson, 
2017) and specific-carbohydrate diet (SCD) (Suskind et al., 2016). Overall, patients in 
remission are encouraged to follow a balanced diet, while in acute phases individual 
intolerances should be considered in alleviating symptoms. However, drastic exclusion 
of foods should be avoided as there is a high risk for nutritional deficiencies, and 
reliable achievement of remission is anyway not established (Forbes et al., 2017).  
The Mediterranean diet (MD) is a dietary regimen characterised by relatively high 
consumption of olive oil, legumes, grains, vegetables, fruits, nuts and seeds, a moderate 
consumption of fish, poultry and dairy foods, but low consumption of processed foods, 
and of red and processed meat. Its proportionally high contents of monounsaturated 
fatty acids, omega-3 polyunsaturated fatty acids, dietary fibre and phytochemicals 
together confer the beneficial anti-inflammatory and antioxidant properties that have 
been documented against chronic diseases (Martinez-Gonzalez & Martin-Calvo, 2016). 
Additionally, MD adherence has been found to beneficially affect the gut microbiota 
and associate metabolome (De Philippis et al., 2016). Since CD is a chronic disease 
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characterised by inflammation and oxidative stress, MD could potentially be beneficial 
for patients and is advocated by IBD clinicians in some parts of the world.  Greek CD 
patients are typically advised by clinicians not to exclude specific food groups and try to 
consume foods from different food groups. However, no specific recommendation as 
regards MD is given, since this dietary regimen has not been formally investigated 
regarding its effect on CD.  
Thus, the aims of the present study were: a) to assess the habitual adherence to MD in 
patients with CD and b) to examine the association of adherence to MD with quality of 
life, disease activity and inflammatory markers.
6 
 
MATERIALS AND METHODS  
 
Ethics  
The protocol was reviewed and approved by the Harokopio University Ethics 
Committee (49/29-10-2015) and the study was conducted according to the principles of 
the Declaration of Helsinki of 1975. Laboratory techniques were standardised and the 
personnel were trained according to Good Clinical Practice.  
 
Participants 
Enrolment was stimulated through an announcement to the Hellenic Society of CD and 
UC patients. Outpatients with endoscopically proven CD were enrolled subject to 
certain inclusion and exclusion criteria. Adult males and females were included. Patients 
were excluded in case of positive stool culture for enteric pathogens or Clostridium 
difficile toxin or when they had undergone bowel surgery ≤3 months prior to screening. 
Additionally, clinically significant short bowel syndrome, the presence of an intra-
abdominal abscess or a fistula with clinical or radiological evidence of an associated 
abscess, ileostomy and colostomy were set as exclusion criteria. Enteral or parenteral 
nutrition, alcohol or drug abuse, vitamin or inorganic supplement use in the 6 months 
prior to screening, a vegan or macrobiotic diet in the 5 years prior to screening, any 
malignancy in the year prior to screening or cancer survivors <10 years, the presence of 
serious cardiovascular disease, peptic ulcer, pregnancy, and lactation were considered as 
exclusion criteria. After receiving full information about the study, participating patients 
provided written Informed Consent, a copy of which was given to the individual. 
Patients were recruited between May 2016 and June 2017. The study took place in 
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Athens, Greece. 
 
Assessment of patients 
Medical history: A gastroenterologist recorded the medical history, including general 
information (e.g. allergic reactions, smoking habits, etc.) as well as specific data 
regarding CD (i.e. brief history of CD, age of diagnosis, complications, treatment). 
Assessment of disease severity was based on the Harvey-Bradshaw Index (ΗΒΙ) 
(Harvey & Bradshaw, 1980). 
Dietary assessment:  
Adherence to MD was evaluated by an experienced dietitian using the MedDiet scoring 
method, which is based on the inherent characteristics of the MD (Supplementary 
material, Table S1). This score was recorded for the mean frequency of consumption of 
each food group in the past 6 months. MedDiet food groups include non-refined cereals, 
fruit, vegetables, legumes, potatoes, fish, meat and meat products, poultry, full fat dairy 
products, as well as olive oil and alcohol. For the consumption of items presumed to be 
close to the Mediterranean Dietary pattern (i.e. those suggested on a daily basis or more 
than 4 servings/week; non-refined cereals, fruits, vegetables, legumes, olive oil, fish, 
and potatoes) the dietitian would assign: a score of 0 for no consumption; 1 for reported 
consumption of 1-4 servings/month; 2 for 5-8 servings/month; 3 for 9-12 
servings/month; 4 for 13-18 servings/month; and a score of 5 for more than 18 
servings/month. For the consumption of foods that are distant from the MD the scores 
are assigned on a reverse scale. For example, for alcohol the score is 5 for consumption 
of less than 100 ml of alcoholic beverages/day, 0 for consumption of more than 700 ml 
of alcoholic beverages/day and 4-1 for consumption of 300, 400-500, 600 and 700 or 0 
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ml of alcoholic beverages/day, respectively. The calculation is based on the central role 
of wine consumption (approx. 12% ethanol) in the Mediterranean diet and 100ml of 
alcoholic bevarages is equivalent with 12g of ethanol. According to this rating scale, the 
MedDiet score ranges from 0 to 55 with higher values indicating greater adherence 
(Panagiotakos et al., 2006).  
An experienced dietitian recorded the 24-hour recall dietary intake and assessed the 
macronutrient and micronutrient composition of the diet with the software package 
Nutritionist Pro™ (Axxya Systems). 
Quality of life assessment: Quality of life was assessed with the Inflammatory Bowel 
Disease Questionnaire (IBDQ). The IBDQ includes 32 questions about bowel habit, 
social, systemic and emotional performance and is scored from 32 to 224 points. Higher 
scores indicate a better quality of life (Guyatt et al., 1989). 
Blood sample collection: Standard blood sampling (20mL) took place. After collection, 
blood samples were centrifuged at 3000rpm for 10 minutes at 4◦C for plasma and serum 
isolation. All samples were stored at -80◦C until further analysis.  
Αnthropometric assessment: Body weight was measured to the nearest 0.1 kg. Height 
was measured with a standard stadiometer to the nearest millimetre. Both measurements 
were performed twice. Body Mass Index (BMI) was also calculated.  
 
Laboratory analyses 
Biochemical analyses: Serum iron (Fe), albumin, glucose, total cholesterol, high-
density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides and plasma 
fibrinogen were quantified with an automatic biochemical analyser. Routine laboratory 
tests included also serum amylase, lactate dehydrogenase (LDH), glutamic-oxaloacetic 
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transaminase (SGOT), glutamic-pyruvic transaminase (SGPT), γ-glutamyl transferase 
(γ-GT), alkaline phospatase (ALP) and C-reactive protein (CRP).  
Serum interleukin (IL)-6 and IL-10 were measured by sandwich ELISA (Biotek 
PowerWave XS2; R&D Systems, Inc. for IL-6, OriGene Technologies, Inc. for IL-10).   
 
Statistical analysis 
Data are expressed as mean ± standard deviation (SD). The differences between two 
independent groups were analysed using Student’s t-test for normally distributed 
variables and Mann-Whitney U test for those not normally distributed. Spearman’s 
correlation tests were used for the correlation analysis. For parameters with a significant 
bivariate association with the MedDiet score, multivariate linear regression models were 
applied. A P value ≤0.05 was considered as significant. Statistical analysis was 
conducted with the SPSS software (SPSS for Windows, version 21.0, SPSS Inc., 
Chicago, IL, USA). 
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RESULTS  
A total of 86 patients diagnosed with CD met our inclusion criteria. Table 1 shows the 
clinical and demographic characteristics of those with active and inactive disease. As 
expected, the HBI was significantly lower in inactive disease (p<0.001), whereas the 
IBDQ score was higher in inactive disease (p<0.001).  The biochemical indices are 
presented in Table 2. Active CD patients had significantly higher levels of fibrinogen 
(p=0.039) and IL-6 (p=<0.001), and lower levels of IL-10 (p=0.025).  
With respect to adherence to MD, the MedDiet score was higher in patients with 
inactive CD than in those with active disease (26.8±5.0 vs 30.2±5.8, p=0.005). Also, 
protein intake (p=0.015) and vitamin C (p=0.003) levels were individually higher in the 
remission group (Τable 3). 
Correlation analyses were conducted for HBI and inflammatory markers with the 
MedDiet score, regardless of remission/relapse status, and the significant associations 
are presented in Table 4. There was a significant negative correlation of the MedDiet 
score with HBI (r = -0.400, P < 0.001) and CRP levels (r = -0.268, P = 0.027), while 
there was a positive correlation of MedDiet score with IBDQ (r = 0.291, P = 0.008). No 
significant correlation was observed between the MedDiet score and IL-6 (p=0.125) or 
between MedDiet and IL-10 (p=0.137).  
Significantly correlated parameters were tested in a linear regression model with an 
adjustment for age, sex and BMI. HBI showed a highly significant negative linear 
correlation with the MedDiet score - B = -0.190 [95%CI: -0.252 to -0.128], (p=0.003), 
whereas IBDQ showed a positive linear correlation with MedDiet score - B = 1.342 
[95%CI: 0.778-1.906], p=0.020). 
Energy intake, carbohydrate, protein, cholesterol, saturated fatty acid, fat, calcium, 
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selenium and iron intake were significantly higher and caffeine intake was significantly 
lower in males with inactive CD than in females (Supplementary material, Table S2).  
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DISCUSSION  
IBD often compromises the nutritional status of patients. Currently international 
guidelines recommend no specific diet for IBD. The effects of the Mediterranean Diet - 
a dietary regimen with several health benefits attributed to its anti-inflammatory and 
antioxidant components – has hitherto been inadequately explored in IBD patients.  
Herein, we identified a higher MedDiet score in patients with inactive CD. Although no 
cut-off values exist in the MedDiet score such that patients could be classified as 
adherent or non-adherent, it is evident that patients in remission are more likely to be 
following a MD. A plethora of different diet scores has been developed in order to study 
overall dietary patterns rather than taking a single nutrient approach to various health 
outcomes. The large scale of the MedDiet score is considered to render it more 
informative when compared with small-scale scores that fail to capture the extremes and 
the inherent characteristics of a pattern or a behaviour, or which may not give good 
predictions in cases where the outcome is of a continuous rather than binary nature 
(Panagiotakos et al., 2006). 
In this study the MedDiet score was negatively associated with HBI and CRP, while it 
was positively associated with IBDQ. When we adjusted for age, sex and BMI, HBI 
showed a highly significant negative linear correlation with the MedDiet score, while 
IBDQ showed a positive linear correlation with MedDiet score. Thus, we hypothesise 
that as adherence to the MD increases, disease activity decreases, leading to an 
improved quality of life.  Another study assessing adherence to MD in CD patients in 
remission using a different tool, namely an adapted 13-item PREDIMED Mediterranean 
Diet Score (P-MDS) showed that only few patients met those criteria for MD, and that 
overall scores were generally low (Taylor et al., 2018). The association of adherence to 
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MD with quality of life in CD may however explain the benefits of low-FODMAP diet 
in CD (Prince et al., 2016), as the latter is replicating in part the MD pattern. 
Our results correspond to those of studies evaluating the association of the MD with 
other chronic inflammatory entities. Veronese and colleagues (2016) showed that 
adherence to the MD is associated with better quality of life, decreased pain, disability 
and depressive symptoms in patients with osteoarthritis, and adherence to the MD was 
associated with better quality of life in patients with type 2 diabetes (Alcubierre et al., 
2016). 
Our protocol has both strengths and limitations. According to our knowledge this is the 
first study that has evaluated adherence to MD and its association with disease activity 
and quality of life in patients with CD. The MedDiet score is a validated tool that allows 
for the prediction of disease risk better than other scores, and was developed to achieve 
analysis of a holistic dietary pattern rather than a single nutrient approach to health 
outcomes. The IBDQ, which is the most widely used tool to assess the quality of life in 
IBD patients (Alrubaiy et al., 2015) is similarly validated, in Greek as well as in English 
(Pallis et al., 2001) and is well respected. The limitations from the modest number of 
participants and the indirect assessment of dietary intake using 24 hour recall, are well 
compensated by the fact that only a single experienced dietitian undertook the interview 
and assessment to avoid biases. 
 
Conclusion 
This study shows for the first time that greater adherence to MD is associated with 
improved quality of life in CD patients and it is negatively associated with disease 
activity. Thus, dietary assessment of CD patients applying simple but validated tools 
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and counselling regarding the MD are likely to be important in the nutritional 
management of CD. Future studies should address implementation of these conclusions.  
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Table 1. Demographic characteristics and clinical features of active and inactive CD 
patients 
 Active (N=41) Inactive (N=45) P 
Age (years) 41.5±16.5 37.4±11.5 0.366 
Sex (female : male) 23:18 18:27  
BMI (kg/m2) 23.0±5.2 24.8±4.2 0.011 
Smoking habit (n%) 15 (36.6%) 16 (35.6%)  
Marital status 
Married 
Unmarried 
Divorced 
 
20 
20 
1 
 
20 
22 
3 
 
Education 
1-9 years 
10-12 years 
>12 years 
 
4 
9 
28 
 
8 
9 
28 
 
Extend of disease 
Colonic 
Ileocolonic 
Ileal 
Other 
 
2 
14 
17 
8 
 
5 
15 
11 
14 
 
Current medical treatment 
Mesalazine  
Azathioprine 
Corticosteroids  
 
9 
9 
17 
 
15 
15 
11 
 
Harvey-Bradshaw index 
(HBI) 
7.3±2.4 2.5±1.2 <0. 001 
IBDQ 144.9±24.0 176.1±25.6 <0.001 
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Table 2. Biochemical indices according to disease activity.  
 Active (N=41) Inactive (N=45) P 
IL-6 (pg/mL) 16.7±16.4 4.8±6.6 <0.001 
IL-10 (pg/mL) 4.9±1.4 5.6±1.6 0.025 
CRP (mg/L) 8.9±9.5 7.0±10.6 0.103 
Amylase (IU/L) 66.2±20.7 71.2±26.7 0.515 
Fibrinogen (mg/dL) 294.1±71.7 259.4±73.7 0.039 
Fe (μg/dL) 66.3±67.1 67.1±34.0 0.250 
Glucose (mg/dL) 84.4±12.4 89.0±15.7 0.170 
Total cholesterol (mg/dL) 168.4±44.0 171.7±45.7 0.809 
HDL (mg/dL) 50.5±14.8 50.8±13.4 0.910 
LDL (mg/dL) 92.1±34.8 98.3±39.7 0.587 
Triglycerides (mg/dL) 128.8±90.9 112.8±62.0 0.246 
Albumin (g/dL) 3.9.±1.3 4.2±0.7 0.439 
SGOT (IU/L) 16.2±9.4 18.6±8.6 0.065 
SGPT (IU/L) 19.2±14.5 19.3±9.6 0.344 
γ-GT (IU/L) 20.9±14.5 27.2±64.4 0.590 
Alkaline phosphatase (IU/L) 67.1±23.8 67.4±36.8 0.541 
Lactate dehydrogenase (U/L) 141.4±31.1 148.7±32.5 0.321 
Values are presented as mean±SD 
Differences between groups were analysed by Mann-Whitney U test or Student's test 
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Table 3. Mediterranean diet score and dietary habits according to disease activity in 
Crohn's disease. 
 Active (N=41) Inactive (N=45) P 
MedDiet score 26.8±5.0 30.2±5.8 0.005 
Energy intake (kcal) 1812.1±646.8 2069.0±825.2 0.309 
Carbohydrates (g) 204.7±85.7 215.4±108.4 0.982 
Proteins (g) 78.3±33.3 100.1±42.2 0.015 
Fats (g) 77.2±40.3 87.1±43.8 0.313 
Cholesterol (mg) 306.4±420.1 288.8±176.1 0.433 
Saturated FA (g) 25.2±13.4 27.2±15.7 0.548 
Monounsaturated FA (g) 33.2±21.1 37.3±23.0 0.272 
Polyunsaturated FA(g) 12.2±8.0 13.4±8.2 0.407 
Oleic acid (g) 27.9±20.0 31.1±21.5 0.326 
Linoleic acid (g) 9.4±7.1 10.5±7.5 0.384 
Linolenic acid (g) 1.15±0.8 1.20±0.8 0.473 
Eicosapentaenoic acid (g) 0.09±0.3 0.07±0.2 0.926 
Docosahexaenoic acid (g) 0.14±0.5 0.15±0.4 0.795 
Trans FA (g) 0.8±1.9 0.4±0.7 0.714 
β-Carotene (μg) 1421.1±2875.3 1739.9±2959.5 0.493 
α-Carotene (μg) 292.8±697.4 471.7±1137.8 0.238 
Lycopene (μg) 4947.0±14561.9 4357.8±7278.0 0.585 
Vitamin C (mg) 46.6±53.1 146.5±490.5 0.003 
Calcium (mg) 755.4±439.1 900.3±508.5 0.192 
Iron (mg) 11.0±4.3 14.1±7.1 0.058 
Vitamin D (μg) 3.3±7.2 2.7±3.0 0.631 
Vitamin E (mg) 0.8±1.8 0.6±1.2 0.465 
a-Tocopherol (mg) 5.9±4.3 6.9±5.5 0.507 
Vitamin K (μg) 57.8±75.0 66.3±66.3 0.300 
Selenium (μg) 100.8±50.6 124.7±70.6 0.077 
Fiber(g) 13.3±8.2 18.8±13.2 0.089 
Glucose (g) 7.5±6.8 10.7±8.9 0.075 
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Lactose (g) 4.5±8.8 4.0±5.8 0.434 
Fructose (g) 9.1±9.1 13.3±12.7 0.118 
Caffeine (mg) 225.2±450.3 313.2±504.0 0.473 
Values are presented as mean±SD. Differences between groups were analysed by Mann-
Whitney U test or Student's test 
FA: fatty acids
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Table 4. Correlation analysis between the MedDiet score and disease activity indices 
and CRP in CD patients. 
 CD patients (N=86) P 
IBDQ 0.291 0.008 
HBI -0.400 <0.001 
CRP (mg/L) -0.268 0.027 
